Your account is not claimed yet. You can sign up with ORCID to claim your account.

Hans-Peter Hartung (Gerd Fätkenheuer, H P Hartung, H-P Hartung, Aiden Haghikia)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 21

Top Venues

Journal of neurology

Annals of neurology

Therapeutic advances in neurological disorders

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Heinrich Heine University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Heinrich Heine University

Germany

Professor and Chairman :: Neurology

Publications

Bruce Anthony Campbell Cree, Rachel Maddux, Amit Bar-Or, Hans-Peter Hartung, Amandeep Kaur, Elizabeth A Brown, Yicong Li, Yanhua Hu, James K Sheffield, Diego Silva, Sarah Harris
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis. Annals of clinical and translational neurology (2023)
Joel Gruchot, Isabel Lewen, Michael Dietrich, Laura Reiche, Mustafa Sindi, Christina Hecker, Felisa Herrero, Benjamin Charvet, Ulrike Weber-Stadlbauer, Hans-Peter Hartung, Philipp Albrecht, Hervé Perron, Urs Meyer, Patrick Küry
Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment. Proceedings of the National Academy of Sciences of the United States of America 120 (38) (2023)
Ingemar S J Merkies, Ivo N van Schaik, Vera Bril, Hans-Peter Hartung, Richard A Lewis, Satomi Mitsuhashi, John-Philip Lawo, Orell Mielke, David R Cornblath, null null
Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the peripheral nervous system : JPNS 27 (2) (2022)
Nik Krajnc, Gabriel Bsteh, Thomas Berger, Jan Mares, Hans-Peter Hartung
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 19 (3) (2022)
Melanie Korsen, Steffen Pfeuffer, Leoni Rolfes, Sven G Meuth, Hans-Peter Hartung
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents. Journal of neurology 269 (5) (2022)
Vinzenz Fleischer, Dumitru Ciolac, Gabriel Gonzalez-Escamilla, Matthias Grothe, Sebastian Strauss, Lara S Molina Galindo, Angela Radetz, Anke Salmen, Carsten Lukas, Luisa Klotz, Sven G Meuth, Antonios Bayas, Friedemann Paul, Hans-Peter Hartung, Christoph Heesen, Martin Stangel, Brigitte Wildemann, Florian Then Bergh, Björn Tackenberg, Tania Kümpfel, Uwe K Zettl, Matthias Knop, Hayrettin Tumani, Heinz Wiendl, Ralf Gold, Stefan Bittner, Frauke Zipp, Sergiu Groppa, Muthuraman Muthuraman, null null
Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Annals of neurology 91 (2) (2022)
Alice G Willison, T Ruck, G Lenz, Hans-Peter Hartung, S G Meuth
The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. Journal of neurology 269 (7) (2022)
Hans-Peter Hartung
Correction to "Hartung H-P. Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making." Annals of neurology 90 (6) (2021)
Heinz Wiendl, Ralf Gold, Thomas Berger, Tobias Derfuss, Ralf A Linker, Mathias Mäurer, Orhan Aktas, Karl Baum, Martin Berghoff, Stefan Bittner, Andrew Chan, Adam Czaplinski, Florian Deisenhammer, Franziska Di Pauli, Renaud Du Pasquier, Christian Enzinger, Elisabeth Fertl, Achim Gass, Klaus Gehring, Claudio Gobbi, Norbert Goebels, Michael Guger, Hans-Peter Hartung, Hans-Peter Hartung, Fedor Heidenreich, Olaf Hoffmann, Boris Kallmann, Christoph Kleinschnitz, Luisa Klotz, Verena I Leussink, Fritz Leutmezer, Volker Limmroth, Jan D Lünemann, Andreas Lutterotti, Sven G Meuth, Uta Meyding-Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S Weber, Uwe K Zettl, Tjalf Ziemssen, Frauke Zipp, null null
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic advances in neurological disorders 14 (2021)
Hans-Peter Hartung
Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making. Annals of neurology 89 (6) (2021)
Ralf Gold, Hans-Peter Hartung, Hans-Peter Hartung, Christoph Kleinschnitz, Reinhard Marks, Matthias Maschke, Antonios Bayas, Micha Löbermann, Uwe K Zettl, Heinz Wiendl
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Therapeutic advances in neurological disorders 14 (2021)
Hans-Peter Hartung, Jan Mares, Sven G Meuth, Thomas Berger
Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 18 (3) (2021)
Nils C Landmeyer, Paul-Christian Bürkner, Heinz Wiendl, Tobias Ruck, Hans-Peter Hartung, Heinz Holling, Sven Guenther Meuth, Andreas Johnen
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. Neurology 94 (22) (2020)
Moritz Förster, Patrick Küry, Orhan Aktas, Clemens Warnke, Joachim Havla, Reinhard Hohlfeld, Jan Mares, Hans-Peter Hartung, David Kremer
Managing Risks with Immune Therapies in Multiple Sclerosis. Drug safety 42 (5) (2020)
F Schweitzer, S Laurent, G R Fink, Michael H Barnett, Hans-Peter Hartung, C Warnke
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. Journal of neurology 268 (7) (2020)
Moritz Förster, Jonas Graf, Jan Mares, Orhan Aktas, Hans-Peter Hartung, David Kremer
Drug Treatment of Clinically Isolated Syndrome. CNS drugs 33 (7) (2020)
Hans-Peter Hartung, null null
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurology(R) neuroimmunology & neuroinflammation 7 (5) (2020)
Jonas Graf, Orhan Aktas, Konrad Rejdak, Hans-Peter Hartung
Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (1) (2019)
Verena Isabell Leussink, Xavier Montalban, Hans-Peter Hartung
Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. CNS drugs 32 (7) (2019)
Hans-Peter Hartung, Jonas Graf, David Kremer
Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of neurology 267 (2) (2019)
Hans-Peter Hartung, R Mallick, V Bril, R A Lewis, Satomi Mitsuhashi, J-P Lawo, O Mielke, B L Durn, D R Cornblath, I S J Merkies, I N van Schaik, null null
Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. European journal of neurology 27 (1) (2019)

Hans-Peter Hartung.css-eqlu8i{font-size:small;padding-left:4px;} (Gerd Fätkenheuer, H P Hartung, H-P Hartung, Aiden Haghikia)

Publication Activity (10 Years)

Top Topics

Top Venues

Hans-Peter Hartung (Gerd Fätkenheuer, H P Hartung, H-P Hartung, Aiden Haghikia)